CorMedix Inc. – Biopharmaceutical Company Focused on Preventing CRBSIs

4小时前发布 1 00

Biopharmaceutical company developing DefenCath to prevent catheter-related bloodstream infections (CRBSIs).

收录时间:
2026-04-22
CorMedix Inc. – Biopharmaceutical Company Focused on Preventing CRBSIsCorMedix Inc. – Biopharmaceutical Company Focused on Preventing CRBSIs

CorMedix Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

The company’s primary focus is on addressing catheter-related bloodstream infections (CRBSIs), a serious healthcare-associated infection. Its lead product candidate is DefenCath® (taurolidine, heparin), which is specifically designed to prevent these infections.

CorMedix operates in the biopharmaceutical industry, targeting critical unmet medical needs in infection control.

数据统计

相关导航

暂无评论

none
暂无评论...